Reed Elsevier PLC

Reed Elsevier NV

January 10, 2005 11:00 ET

MDL Isentris Selected by Novo Nordisk to Integrate R&D Informatics and Workflow


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: REED ELSEVIER PLC

NYSE SYMBOL: RUK
AEX SYMBOL: REN.AS

AND REED ELSEVIER NV

NYSE SYMBOL: ENL
LSE SYMBOL: REL.L

JANUARY 10, 2005 - 11:00 ET

MDL Isentris Selected by Novo Nordisk to Integrate R&D
Informatics and Workflow

SAN LEANDRO, Calif.--(CCNMatthews - Jan 10, 2005) -

Elsevier MDL is pleased to announce that Novo Nordisk has selected the
MDL® Isentris® information management and integration platform for
its R&D operations. Isentris is the first fully supported,
open-standards-based, n-tier discovery informatics platform specifically
designed for life sciences researchers. Designed to operate over a Wide
Area Network, Isentris is unique in integrating business processes, data
and applications across R&D. Novo Nordisk is already using the
DiscoveryGate® product, which is built on Isentris and provides
one-query access to the world's largest integrated environment of
chemical, pharmacological and patent databases.

"Isentris is our most ambitious product to date and accelerates R&D by
providing a free flow of internal and external information, rapid
deployment of new workflows and flexible project views," said Lars
Barfod, president and chief executive officer of Elsevier MDL. "We are
delighted that Novo Nordisk has elected to build their new, modern R&D
information architecture on our flagship enterprise software."

Novo Nordisk has licensed the entire MDL® Isentris® Enterprise
Edition platform, which includes the revolutionary MDL® Base user
interface, MDL® Draw chemical drawing and rendering software, MDL®
Core Interface middle tier with Integrating Data Source and the MDL®
Direct chemical data cartridges for molecules and reactions. Full
compatibility with MDL ISIS ensures easy migration to Isentris.

To learn more about how MDL Isentris integrates and energizes life
sciences discovery, contact your Elsevier MDL Account Manager, or
request information using the "Contact Us" form available at www.mdl.com.

About Elsevier MDL

Elsevier MDL provides informatics, database, workflow and decision
support solutions that accelerate the discovery and development of
successful new drugs by improving the speed and quality of scientists'
decision making. Commercial, academic and government life sciences
researchers around the world depend on Elsevier MDL for innovative and
reliable discovery informatics software solutions and services augmented
by 400 Elsevier chemistry and life sciences journals and related
products. For more information, visit www.mdl.com.

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with
the global science and health communities, the company publishes more
than 1,800 journals and 2,200 new books per year, in addition to
offering a suite of innovative electronic products, online reference
works and subject-specific portals. For more information, visit
www.elsevier.com.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher
and information provider. Reed Elsevier's ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York
Stock Exchange). For more information, visit www.reedelsevier.com.

MDL, Isentris and DiscoveryGate are registered trademarks in the United
States, and "Powering the Process of Invention" is a trademark of MDL
Information Systems, Inc. in the United States and other countries. All
rights reserved.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Elsevier MDL
    Dr. Phil McHale, 510-357-2222 ext. 3541
    email: p.mchale@mdl.com